Clinigen Group Plc (AIM:CLIN) acquired Cardioxane(R) from Novartis AG (SWX:NOVN) for $33 million in cash on March 26, 2013. The purchase price is payable in two tranches. Cardioxane reported revenues of $12 million for the year 2012. James Black, Tom Ballard, Michael Meade and Freddie Barnfield of Numis Securities Limited acted as financial advisor for Clinigen Group. Melanie Toyne-Sewell, Stefanie Bacher and Jen Lewis of College Hill acted as public relations advisor ... for Clinigen.
Read More

Rottapharm S.p.A. acquired Zyma® brands in 19 Countries from Novartis AG (SWX:NOVN) on March 12, 2013. Sophie Hagege of Jones Day acted as legal advisor for Novartis. Plexus Ventures provided professional services to Novartis. Claudio Rossetti and Marianna Cerina of Echo Comunicazione d'impres acted as public relations advisors in the transaction.

Novartis AG (SWX:NOVN) acquired Vivacta Limited from HBM Healthcare Investments AG (SWX:HBMN), fund of HBM Partners Ltd., Albion Ventures LLP, SPARK Ventures plc (AIM:SPK), IDInvest Partners, Viking Venture AS and other investors for $90 million on December 17, 2012. The deal value is subject to post-closing adjustments.

Vivalis (ENXTPA:VLS) agreed to acquire Intercell Ag (WBAG:ICLL) from Novartis AG (SWX:NOVN), MDO Management Company, Glaxosmithkline Biologicals S.A. and other shareholders for approximately €130 million in stock in a merger of equals on December 16, 2012. Intercell shareholders will receive 13 Vivalis new ordinary shares for every 40 Intercell shares. Post completion, the combined entity will be held 55% by former Vivalis shareholders and 45% by former Intercell shareholders. ... Irrevocable undertakings to vote in favor of the merger have been received from holders of 68.5% of the voting rights in Vivalis. Vivalis and Intercell AG will merge to form Valneva SE headquartered in Lyon (France) and listed on the regulated markets of NYSE Euronext in Paris and the Vienna Stock Exchange. Valneva will be led by Thomas Lingelbach, the head of Intercell. Franck Grimaud, Chairman of the Management Board of Vivalis, will become Chief Business Officer of Valneva. The Merger of Equals structure will mean that each company will contribute equally to Valneva’s Supervisory Board, and Valneva’s Management Board will be comprised of two Vivalis and two Intercell Management Board members. The merger has been unanimously approved by the Supervisory Boards of Vivalis and Intercell. The merger is subject to certain customary conditions, including, inter alia, the approval by shareholders of both Vivalis and Intercell and the obtaining of relevant regulatory consents. The transaction is expected to complete in May, 2013. On December 17, 2012, Fonds stratégique d'investissement concluded a protocol agreement in order to subscribe up to €25 million of a capital increase of an estimated amount of €40 million of the new unit, renamed Valneva. Groupe Grimaud and Unigrains have also committed to subscribing to the capital increase within the limit of a total amount of €5 million. As of February 27, 2013 all resolutions were approved by the Extraordinary Shareholders meeting of Intercell for the proposed merger. The general meeting of Vivalis SA will take place on March 7, 2013. As of March 7, 2013, shareholders of Vivalis SA approved the transaction. On May 14, 2013, it was announced that the final administrative step for closing of the proposed merger to create Valneva SE has been initiated by filing of the relevant documents with the companies' register at the Commercial Court of Lyon. The step follows the issuance of the pre-merger certificates by the French Commercial Register on April 3, 2013 and by the Austrian Commercial Register on April 12, 2013, and the issuance of the certificate of legality of the merger on April 17, 2013. Subject to the registration decision by the Court of Lyon, the completion of the merger is expected for May 28, 2013. Goldman Sachs International and Rodolphe Besserve, Jean-Baptiste Billy, Nicolas Genès of SG Corporate & Investment Banking are acting as financial advisors to Intercell and Vivalis in the transaction respectively. Axelle Vuillermet and Pierre Laurent of NewCap acted as public relations advisors to Vivalis in the transaction. Jean-Marc Franceschi and Arnaud Deparday of Hogan Lovells (Paris) LLP acted as legal advisors for Vivalis. Stanislas de Gastines, Helen Pelzmann, Mario Gall acted as financial adue diligence advisor and Bernard Martinier of Ernst & Young Société d’Avocats acted as legal advisor for Vivalis. Alan Mason, Guillemette Burgala, Sibylle Renard-Payen, Sami Jebbour, Cyril Valentin, Laurent Dabernat, Christopher Ivey of Freshfields acted as legal advisor for Intercell Ag. Kristelle Kerforn of CA CIB acted as financial advisor, Marc Castagnède, Jean-Baptiste de Martigny of Allen & Overy acted as legal advisor for FSI and other shareholders in capital increase.
Read More

PeptiDream Inc. announced that it has raised approximately ¥620,000,000 in equity funding from new investor, Novartis AG on December 1, 2012. The investor gained 3.75% stake in the company through third party allocation.

Sponsored Financial Commentaries

To contact NOVARTIS AG-ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.